Updated:
Theriva Biologics, Inc.
Theriva Biologics (NYSE American: TOVX) develops therapeutics for diseases in areas of high unmet need. The company entered oncology through the acquisition of...
Theriva Biologics, Inc.
Theriva Biologics (NYSE American: TOVX) develops therapeutics for diseases in areas of high unmet need. The company entered oncology through the acquisition of VCN Biosciences, S.L. VCN developed an oncolytic adenovirus platform for intravenous, intravitreal, and intratumoral delivery that triggers tumor cell death, improves access of co-administered cancer therapies to the tumor, and promotes a sustained anti-tumor response by the patient’s immune system.
General information
Firm type
other
Frequently asked questions
Who runs investment decisions at Theriva Biologics?
Theriva Biologics is a publicly traded company (OTCQB: TOVX), so investment decisions are overseen by its board of directors and executive management team. The company's leadership includes a CEO and senior executives responsible for strategic direction and capital allocation (per SEC filings).
How does Theriva Biologics source proprietary deal flow?
Theriva Biologics primarily advances internally developed product candidates from its proprietary technology platforms. The company also engages in licensing agreements and collaborations with academic institutions and research organizations to expand its pipeline (per the firm's annual report, 2023).
Is Theriva Biologics structured as a single family office or does it operate more like a venture firm?
Theriva Biologics is a clinical-stage biopharmaceutical company, not a family office or venture firm. It operates as a publicly traded entity focused on drug development, with family offices and institutional investors among its shareholders.
What investment stages does Theriva Biologics typically target?
As a therapeutic developer, Theriva Biologics focuses on preclinical through Phase 2 clinical trials. The company's pipeline consists of candidates at various stages of development, with the most advanced programs in Phase 1 or Phase 2 clinical studies (per clinicaltrials.gov).
Which sectors does Theriva Biologics invest in?
Theriva Biologics is not an investment firm; it is a biopharmaceutical company developing therapies for oncology and rare diseases. The company's pipeline targets solid tumors and genetic disorders, reflecting a focus on high-unmet-need therapeutic areas.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: